Updates are available Correction dated 2023-11-02
Click to view Correction: https://doi.org/10.1038/s41698-023-00469-7
-
Authors
Khani, Francesca http://orcid.org/0000-0001-7238-8604
Hooper, William F.
Wang, Xiaofei http://orcid.org/0000-0001-7223-6950
Chu, Timothy R.
Shah, Minita
Winterkorn, Lara
Sigouros, Michael http://orcid.org/0000-0002-0328-8359
Conteduca, Vincenza http://orcid.org/0000-0002-6921-714X
Pisapia, David
Wobker, Sara
Walker, Sydney
Graff, Julie N.
Robinson, Brian http://orcid.org/0000-0001-5374-890X
Mosquera, Juan Miguel http://orcid.org/0000-0003-4666-6476
Sboner, Andrea http://orcid.org/0000-0001-6915-3070
Elemento, Olivier http://orcid.org/0000-0002-8061-9617
Robine, Nicolas
Beltran, Himisha http://orcid.org/0000-0003-3259-2226
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (5R37CA241486-03)
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (P50CA211024)
- License Information
-
More Information
Article History
Received: 6 February 2023
Accepted: 8 August 2023
First Online: 13 September 2023
Change Date: 2 November 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41698-023-00469-7
Competing interests
: V.C. has served as a consultant/advisory board member for Janssen, Astellas, Merck, AstraZeneca, Amgen and Bayer and has received speaker honoraria or travel support from Astellas, Janssen, Ipsen, Bayer and BMS. O.E is cofounder of Volastra Therapeutics and OneThree Biotech, has served as consultant/advisory board member of Owkin, Freenome, Genetic Intelligence, Acuamark DX, Harmonic Discovery, and Champions Oncology (SAB member and consultant) and has received research funding from Eli Lilly, J&J/Janssen, Sanofi, AstraZeneca and Volastra. H.B. has served as consultant/advisory board member for Janssen, Merck, Pfizer, Foundation Medicine, Blue Earth Diagnostics, Amgen, Bayer, Oncorus, LOXO, Daicchi Sankyo, Sanofi, Curie Therapeutics, Astra Zeneca, Novartis, and has received research funding from Janssen, Bristol Myers Squibb, Circle Pharma, Daicchi Sankyo, Novartis. The remaining authors declare no competing interests.
